We conducted a prospective , multicenter , randomized phase III trial in patients with unresectable , chemotherapy-refractory liver-limited metastatic CRC ( mCRC ) comparing arm A ( fluorouracil [ FU ] protracted intravenous infusion 300 mg/m ( 2 ) days 1 through 14 every 3 weeks ) and arm B ( radioembolization plus intravenous FU 225 mg/m ( 2 ) days 1 through 14 then 300 mg/m ( 2 ) days 1 through 14 every 3 weeks ) until hepatic progression .
